Positive News SentimentPositive NewsNASDAQ:TENX Tenax Therapeutics (TENX) Stock Price, News & Analysis $6.25 +0.10 (+1.63%) Closing price 05/30/2025 03:47 PM EasternExtended Trading$6.14 -0.12 (-1.84%) As of 05/30/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tenax Therapeutics Stock (NASDAQ:TENX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tenax Therapeutics alerts:Sign Up Key Stats Today's Range$6.05▼$6.3150-Day Range$5.10▼$6.5552-Week Range$2.77▼$7.89Volume2,631 shsAverage Volume159,854 shsMarket Capitalization$25.93 millionP/E RatioN/ADividend YieldN/APrice Target$17.50Consensus RatingBuy Company OverviewTenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.Read More… Tenax Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreTENX MarketRank™: Tenax Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 798th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingTenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenax Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Tenax Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tenax Therapeutics are expected to decrease in the coming year, from ($0.88) to ($3.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenax Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenax Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenax Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tenax Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.55% of the float of Tenax Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Tenax Therapeutics has recently increased by 0.65%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenax Therapeutics does not currently pay a dividend.Dividend GrowthTenax Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.55% of the float of Tenax Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Tenax Therapeutics has recently increased by 0.65%, indicating that investor sentiment is decreasing. News and Social Media3.8 / 5News SentimentN/A News SentimentTenax Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tenax Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for TENX on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.14% of the stock of Tenax Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 1.67% of the stock of Tenax Therapeutics is held by institutions.Read more about Tenax Therapeutics' insider trading history. Receive TENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TENX Stock News HeadlinesTenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comTenax Therapeutics Inc.May 9, 2025 | barrons.comDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.May 31, 2025 | Colonial Metals (Ad)Tenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsApril 16, 2025 | seekingalpha.comTenax Therapeutics files to sell 4.14M shares of common stock for holdersApril 16, 2025 | markets.businessinsider.comTenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTenax Therapeutics reports Q4 EPS (18c), consensus (43c)March 27, 2025 | markets.businessinsider.comTenax Therapeutics (TENX) Gets a Buy from William BlairMarch 27, 2025 | markets.businessinsider.comSee More Headlines TENX Stock Analysis - Frequently Asked Questions How have TENX shares performed this year? Tenax Therapeutics' stock was trading at $6.19 at the start of the year. Since then, TENX shares have increased by 1.0% and is now trading at $6.25. View the best growth stocks for 2025 here. How were Tenax Therapeutics' earnings last quarter? Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its earnings results on Wednesday, May, 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. When did Tenax Therapeutics' stock split? Shares of Tenax Therapeutics reverse split on Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Tenax Therapeutics' major shareholders? Tenax Therapeutics' top institutional investors include ADAR1 Capital Management LLC (1.66%). View institutional ownership trends. How do I buy shares of Tenax Therapeutics? Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenax Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenax Therapeutics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Broadcom (AVGO) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings5/14/2025Today5/31/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TENX CIK34956 Webwww.tenaxthera.com Phone919-855-2100Fax919-855-2133Employees9Year Founded1967Price Target and Rating Average Stock Price Target$17.50 High Stock Price Target$20.00 Low Stock Price Target$15.00 Potential Upside/Downside+180.0%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.71 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.00% Return on Assets-42.65% Debt Debt-to-Equity RatioN/A Current Ratio38.95 Quick Ratio38.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$27.15 per share Price / Book0.23Miscellaneous Outstanding Shares4,148,000Free Float3,283,000Market Cap$25.93 million OptionableNot Optionable Beta1.92 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TENX) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.